ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics   a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May 17^th from 2:05 - 2:30 p.m. ET at the upcoming 2022 RBC Capital Markets Global Healthcare Conference being held in New York City from May 17-18, 2022.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005071/en/